fluorouracil has been researched along with Chronic Kidney Failure in 30 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We sought to evaluate the pharmacokinetics of cisplatin and 5-fluorouracil in plasma and peritoneal dialysate in a patient being treated for esophageal adenocarcinoma." | 3.83 | A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. ( Beumer, JH; Eads, JR; Holleran, JL; Meropol, NJ; Negrea, L; Strychor, S, 2016) |
| "A 64-year-old man on chronic hemodialysis for end-stage renal disease developed peritoneal carcinomatosis, and palliative chemotherapy with fluorouracil was started." | 3.73 | Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure. ( Cartei, G; Ferrari, M; Ferrazzi, E; Gusella, M; Padrini, R; Rebeschini, M, 2005) |
| "Following gastrectomy for locally advanced adenocarcinomas, three patients developed microangiopathic hemolytic anemia and renal failure shortly after completing courses of adjuvant chemotherapy with mitomycin and 5-FU." | 3.66 | Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome. ( Band, PR; Bettez, P; Giroux, L; Gruber, J; Jolivet, J; Laurin, S, 1983) |
| "Fourteen patients with adenocarcinoma of the gastrointestinal tract and pancreas treated with mitomycin C(MMC) and 5-fluorouracil (5-FU) had renal impairment 6-11 months from the beginning of MMC therapy." | 3.66 | Renal disease after mitomycin C therapy. ( Hanna, WT; Krauss, S; Murphy, WM; Regester, RF, 1981) |
| "A 72 year old man with rectal adenocarcinoma developed chronic renal failure when treated by surgery and subsequent chemotherapy (5-fluorouracil, Mitomycin C and Cytosine arabinoside) and immunotherapy." | 3.66 | Severe glomerular mesangiolysis in a patient with rectal adenocarcinoma treated with cytotoxic drugs. ( Fornari, G; Mazzucco, G; Monga, G, 1982) |
| " Alternatively, the concept of prior dosing allows for the application of dialyzable chemotherapeutic drugs using a normal dose, with an HD followed shortly after to mimic normal renal function." | 2.58 | Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review . ( Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T, 2018) |
| "Here, we report a case with recurrence of rectal cancer who received FOLFIRI with bevacizumab chemotherapy under haemodialysis, and obtained good tumor control." | 2.48 | [FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure]. ( Endo, T; Hasegawa, H; Hoshino, G; Hoshino, H; Hoshino, Y; Ishii, Y; Kitagawa, Y; Matsunaga, A; Ochiai, H; Seo, Y; Shigeta, K, 2012) |
| "Capecitabine (Xeloda) is an orally administered precursor of 5'deoxy-5-fluorouridine, which is a preferentially activated to 5-fluorouracil in tumors." | 1.38 | A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis. ( Flombaum, C; Jhaveri, KD; Latcha, S; Shah, M, 2012) |
| " The CDDP dosage was reduced to 40% and HD was started 30 minutes after CDDP administration." | 1.35 | [Successful treatment with 5-fluorouracil and cis-dichlorodiammineplatinum combined with 60Gy of radiation in a case of advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis]. ( Arai, Y; Hotta, K; Miyata, Y; Oyama, T; Tomori, A, 2008) |
| " The dosage of each drug was based on that for a patient undergoing hemodialysis, and the plasma concentration of each drug was examined." | 1.33 | [Chemotherapy for an esophageal cancer patient undergoing continuous ambulatory peritoneal dialysis for chronic renal failure and measurement of plasma concentration of the drug]. ( Maruyama, K; Motoyama, S; Ogawa, J; Ohta, H; Okuyama, M; Oyake, J; Tsuchiya, N, 2005) |
| " S-1 has safe and potent antitumor effects in patients with gastric cancer via these respective functions." | 1.32 | Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis. ( Arakawa, T; Fujiwara, Y; Hamaguchi, M; Higuchi, K; Matsumoto, T; Okazaki, H; Oshitani, N; Sasaki, E; Shiba, M; Suto, R; Tanigawa, T; Tominaga, K; Watanabe, T, 2004) |
| " Because no data are available for patients with severe renal failure, the pharmacokinetic parameters of 5-FU and its catabolites were determined for a patient with colorectal carcinoma and end-stage renal disease on maintenance hemodialysis therapy." | 1.31 | Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. ( Bommer, J; Göggelmann, C; Hull, WE; Rengelshausen, J; Schwenger, V; Walter-Sack, I, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (16.67) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Maruta, M | 1 |
| Miyoshi, T | 1 |
| Matsuo, N | 1 |
| Yamashina, T | 1 |
| Irie, K | 1 |
| Tsuruta, M | 1 |
| Tsukada, H | 1 |
| Tsuruyama, M | 1 |
| Nagano, M | 1 |
| Hiraki, Y | 1 |
| Hann, A | 1 |
| Nosalski, E | 1 |
| Hermann, PC | 1 |
| Egger, J | 1 |
| Seufferlein, T | 1 |
| Keller, F | 1 |
| Bolonesi, RM | 1 |
| Rogers, JE | 1 |
| Shureiqi, I | 1 |
| Gori, S | 1 |
| Lunardi, G | 1 |
| Inno, A | 1 |
| Magarotto, R | 1 |
| Duranti, S | 1 |
| Messa, MG | 1 |
| Mucchino, C | 1 |
| Cirillo, M | 1 |
| Eads, JR | 1 |
| Beumer, JH | 1 |
| Negrea, L | 1 |
| Holleran, JL | 1 |
| Strychor, S | 1 |
| Meropol, NJ | 1 |
| Takeda, T | 1 |
| Miyake, M | 2 |
| Tanaka, K | 1 |
| Uemura, M | 1 |
| Ikeda, M | 1 |
| Maeda, S | 1 |
| Yamamoto, K | 1 |
| Hama, N | 1 |
| Nishikawa, K | 1 |
| Miyamoto, A | 1 |
| Miyazaki, M | 1 |
| Hirao, M | 1 |
| Nakamori, S | 1 |
| Sekimoto, M | 1 |
| Arai, Y | 1 |
| Oyama, T | 1 |
| Hotta, K | 1 |
| Tomori, A | 1 |
| Miyata, Y | 1 |
| Saito, Y | 1 |
| Shimada, K | 1 |
| Ohno, Y | 1 |
| Toshima, H | 1 |
| Kobayashi, K | 1 |
| Miyashita, K | 1 |
| Tsuchiya, S | 1 |
| Takinishi, Y | 1 |
| Miyokawa, A | 1 |
| Itoh, T | 1 |
| Sakashita, A | 1 |
| Kuwabara, H | 1 |
| Baba, H | 2 |
| Wakabayashi, M | 1 |
| Nakamura, H | 1 |
| Sanada, T | 1 |
| Nakajima, K | 1 |
| Goseki, N | 1 |
| Jhaveri, KD | 1 |
| Flombaum, C | 1 |
| Shah, M | 1 |
| Latcha, S | 1 |
| Hoshino, H | 1 |
| Ishii, Y | 1 |
| Hasegawa, H | 1 |
| Endo, T | 1 |
| Ochiai, H | 1 |
| Hoshino, Y | 1 |
| Matsunaga, A | 1 |
| Shigeta, K | 1 |
| Seo, Y | 1 |
| Hoshino, G | 1 |
| Kitagawa, Y | 1 |
| Kitade, H | 1 |
| Shimasaki, T | 1 |
| Yoshimitsu, Y | 1 |
| Okuda, M | 1 |
| Hokkoku, K | 1 |
| Mori, M | 1 |
| Shintaku, K | 1 |
| Sakuma, H | 1 |
| Ueda, H | 1 |
| Nakai, M | 1 |
| Tominaga, K | 1 |
| Higuchi, K | 1 |
| Okazaki, H | 1 |
| Suto, R | 1 |
| Hamaguchi, M | 1 |
| Tanigawa, T | 1 |
| Sasaki, E | 1 |
| Shiba, M | 1 |
| Watanabe, T | 1 |
| Fujiwara, Y | 1 |
| Oshitani, N | 1 |
| Matsumoto, T | 1 |
| Arakawa, T | 1 |
| Tanaka, T | 1 |
| Fujita, S | 1 |
| Tanaka, N | 2 |
| Ooka, M | 1 |
| Okajima, S | 1 |
| Okuyama, M | 1 |
| Motoyama, S | 1 |
| Maruyama, K | 1 |
| Ohta, H | 1 |
| Tsuchiya, N | 1 |
| Oyake, J | 1 |
| Ogawa, J | 1 |
| Gusella, M | 1 |
| Rebeschini, M | 1 |
| Cartei, G | 1 |
| Ferrazzi, E | 1 |
| Ferrari, M | 1 |
| Padrini, R | 1 |
| Cicin, I | 1 |
| Karagol, H | 1 |
| Uzunoglu, S | 1 |
| Uygun, K | 1 |
| Vénat-Bouvet, L | 1 |
| Saint-Marcoux, F | 1 |
| Lagarde, C | 1 |
| Peyronnet, P | 1 |
| Lebrun-Ly, V | 1 |
| Tubiana-Mathieu, N | 1 |
| Ohnishi, T | 1 |
| Kanoh, T | 1 |
| Shiozaki, K | 1 |
| Kimura, Y | 1 |
| Iwazawa, T | 1 |
| Tono, T | 1 |
| Nakano, Y | 1 |
| Yano, K | 1 |
| Mizuno, H | 1 |
| Shin, S | 1 |
| Monden, T | 1 |
| Jolivet, J | 1 |
| Giroux, L | 1 |
| Laurin, S | 1 |
| Gruber, J | 1 |
| Bettez, P | 1 |
| Band, PR | 1 |
| Hanna, WT | 1 |
| Krauss, S | 1 |
| Regester, RF | 1 |
| Murphy, WM | 1 |
| Mazzucco, G | 1 |
| Fornari, G | 1 |
| Monga, G | 1 |
| Watanabe, A | 1 |
| Saito, T | 1 |
| Sakamoto, K | 1 |
| Arita, S | 1 |
| Hisikawa, E | 1 |
| Yaguchi, H | 1 |
| Arima, H | 1 |
| Matsumoto, M | 1 |
| Hachisu, T | 1 |
| Kashiwabara, H | 1 |
| Yokoyama, T | 1 |
| Maruyama, M | 1 |
| Irie, T | 1 |
| Yoshida, T | 1 |
| Nagahama, T | 1 |
| Sugano, N | 1 |
| Ebuchi, M | 1 |
| Cho, H | 1 |
| Imada, T | 1 |
| Masudo, K | 1 |
| Doi, C | 1 |
| Inaba, M | 1 |
| Tokunaga, M | 1 |
| Takanashi, Y | 1 |
| Iwasaki, A | 1 |
| Tanizaki, A | 1 |
| Ohbayashi, Y | 1 |
| Nagahata, S | 1 |
| Takahashi, N | 1 |
| Rengelshausen, J | 1 |
| Hull, WE | 1 |
| Schwenger, V | 1 |
| Göggelmann, C | 1 |
| Walter-Sack, I | 1 |
| Bommer, J | 1 |
| Claycomb, CL | 1 |
| Berkovic, M | 1 |
| Tamura, J | 1 |
| Kamano, T | 1 |
| Azuma, N | 1 |
| Katami, A | 1 |
| Sato, T | 2 |
| Uchida, N | 1 |
| Kanno, T | 1 |
| Kiyatake, I | 1 |
| Kakuhara, T | 1 |
2 reviews available for fluorouracil and Chronic Kidney Failure
| Article | Year |
|---|---|
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carci | 2018 |
[FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
1 trial available for fluorouracil and Chronic Kidney Failure
| Article | Year |
|---|---|
[Pharmacokinetic study of UFT in cancer patients receiving maintenance dialysis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1995 |
27 other studies available for fluorouracil and Chronic Kidney Failure
| Article | Year |
|---|---|
Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Fluorouracil; Huma | 2021 |
A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2014 |
Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response | 2014 |
A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dialysis Solutions; Esoph | 2016 |
[XELOX plus Bevacizumab Chemotherapy for a Patient with Postoperative Recurrence of Colorectal Cancer Under Hemodialysis for Chronic Renal Failure].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Combined | 2015 |
[Successful treatment with 5-fluorouracil and cis-dichlorodiammineplatinum combined with 60Gy of radiation in a case of advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2008 |
[5-FU/l-LV therapy is useful for hemodialysis patients with advanced gastric cancer].
Topics: Aged; Biopsy; Fluorouracil; Humans; Kidney Failure, Chronic; Leucovorin; Male; Neoplasm Staging; Ren | 2011 |
[mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2011 |
A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Creatinine; Deoxycytidine; D | 2012 |
[A case of colon cancer with chronic renal dysfunction responding to effective retreatment with FOLFIRI].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; | 2012 |
Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Topics: Administration, Oral; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Kidney | 2004 |
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedu | 2005 |
[Chemotherapy for an esophageal cancer patient undergoing continuous ambulatory peritoneal dialysis for chronic renal failure and measurement of plasma concentration of the drug].
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Dose-Response Relations | 2005 |
Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure.
Topics: Antimetabolites, Antineoplastic; Fluorouracil; Humans; Injections, Intravenous; Kidney Failure, Chro | 2005 |
Efficient and safe application of a FOLFIRI/bevacizumab combination to a patient with locally advanced rectal cancer and severe chronic renal failure.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2007 |
[FOLFOX 4 in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Routes; Female; Fluorourac | 2007 |
Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome.
Topics: Adenocarcinoma; Adult; Anemia, Hemolytic; Drug Therapy, Combination; Female; Fluorouracil; Humans; K | 1983 |
Renal disease after mitomycin C therapy.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Blood Pressure; Blood Urea Nitrogen; Creatinine; F | 1981 |
Severe glomerular mesangiolysis in a patient with rectal adenocarcinoma treated with cytotoxic drugs.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cytarabine; Fluorescent Antibody Technique; Fluorouraci | 1982 |
[Treatment of tongue squamous cell carcinoma under hemodialysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1995 |
[Hemodynamics at hepatoarterial infusion of 5-FU in a chronic renal failure patient maintained by hemodialysis].
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; I | 1999 |
[Combined 5-FU and CDDP in a gastric cancer patient undergoing hemodialysis--pharmacokinetics of 5-FU and CDDP].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fema | 2000 |
[Chemotherapy with nedaplatin for an oral floor cancer patient undergoing chronic hemodialysis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration | 2000 |
Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colonic Neoplasms; | 2002 |
Microangiopathic hemolytic anemia, noncardiac pulmonary edema, and renal failure after treatment of metastatic adenocarcinoma of the colon with 5-fluorouracil and mitomycin-C: report of a case.
Topics: Adenocarcinoma; Anemia, Hemolytic; Colonic Neoplasms; Female; Fluorouracil; Humans; Kidney Failure, | 1986 |
[Absorption of 5-FU orally administered in a patient with postoperative gastric cancer under artificial dialysis].
Topics: Administration, Oral; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans; Kidney Failure, | 1987 |